This will be of clinical relevance to decide management strategies to ameliorate the progress of early stages of cardiac dysfunction in the future, and if positive would provide justification for longer term, prospective trials on the potential benefits of GLP-1 agonists to prevent heart failure in this population. This evidence concerns the gene GLP1R and heart failure.